Gain insight on Centene, China’s pharmaceutical sector and more in the latest Market Talks covering the Health Care sector.

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

From AI integration to workforce development, health system marketing leaders are making targeted investments in 2025 aimed at boosting engagement, strengthening strategy alignment and driving ...

With tariffs looming and pricing policies shifting, life sciences companies may be on the cusp of “pivotal moment,” according ...

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...

Inaugural 'Innovation Catalyst' event empowers innovators at UConn Health to transform their exciting research ideas into ...

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part of talks with the U.S. government, which is pressuring drugmakers to cut ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...

PEPFAR, the campaign to end H.I.V. globally, would morph into an effort to detect disease outbreaks and sell American ...

While FDA Commissioner Marty Makary emphasizes learning and humility, the FDA has systematically removed the very experience ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...